Platelet-derived growth factor BB
proteinPDGF-BB released from activated platelets amplifies plaque inflammation and predicts microvascular thrombosis and no-reflow in acute coronary occlusion.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationalePlatelet α-granule release product; predicts microvascular reperfusion failure (no-reflow) in STEMI.
Also acts inMyocardial injury
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I50
C — confounder / Type-II67
A — assay feasibility68
E — evidence strength26
T1DI (composite)7
Specificity differential (R−C)-17.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Targeted delivery of engineered adipose-derived stem cell secretome to promote cardiac repair after myocardial infarction.Journal of controlled release : official journal of the Controlled Release Society · 2025 · PMID 40274072 · doi
- Platelet-derived growth factor-BB is a novel inflammatory biomarker of no-reflow in STEMI patients treated with primary PCI.Journal of thrombosis and thrombolysis · 2025 · PMID 41071256 · doi